Glucotrack Poised to Revolutionize Continuous Glucose Monitoring with Innovative Implantable Device

Glucotrack Inc. (NASDAQ: GCTK), a medical technology company based in Rutherford, New Jersey, is positioning itself to revolutionize the continuous glucose monitoring (CGM) market. The company has developed an implantable Continuous Blood Glucose Monitor (CBGM) that claims to address several issues prevalent in existing CGM devices, such as the need for frequent sensor changes and concerns about comfort and wearability.

Unlike most CGM devices that measure glucose in interstitial fluids, Glucotrack’s CBGM measures glucose directly in the blood, offering users an accurate, real-time reading. This device can last up to three years, significantly longer than the less-than-one-year lifespan of many current CGM products. Additionally, it eliminates the need for adhesive wearables, which can be cumbersome and unreliable during physical activities.

Glucotrack has been actively promoting its CBGM technology, presenting two posters at the American Diabetes Association (ADA) 84th Scientific Sessions in June. These presentations discussed preclinical animal studies and sensor longevity simulation modeling for the CBGM. The ADA Scientific Sessions are a key platform for the latest advancements in diabetes research and care.

In August, Glucotrack presented another poster at the Association of Diabetes Care and Education Specialists annual conference. This presentation highlighted market research data showing positive sentiment toward the CBGM concept among people with type 1 and type 2 diabetes. Over 50% of the 757 respondents indicated they were open to adopting the product, suggesting that Glucotrack’s CBGM could be a viable alternative to existing glucose monitoring solutions.

Recent preclinical trials have further validated Glucotrack’s claims. A 90-day preclinical study demonstrated the sustained accuracy of its CBGM, showing a Mean Absolute Relative Difference (MARD) of 4.7% at day 90. MARD is a crucial metric for assessing the accuracy of glucose monitoring devices, and lower values indicate better performance.

Paul Goode, PhD, the president and CEO of Glucotrack, expressed optimism about the CBGM’s potential to improve the quality of life for people with diabetes by offering a more convenient and discreet monitoring solution. The company recently secured $4 million in funding from its leading shareholder to support upcoming human clinical trials.

Glucotrack’s leadership team boasts extensive experience in the medical technology industry. Notably, Goode has decades of experience in developing implantable and glucose monitoring technologies, including work at DexCom Inc. (NASDAQ: DXCM). The company also recently appointed Andy Balo, a former DexCom executive, to its board of directors, further strengthening its expertise in regulatory, clinical, and quality matters.

With the continuous glucose monitoring market forecasted to grow at a compound annual growth rate (CAGR) of 10.3% over the next decade, Glucotrack aims to expand options for patients with its innovative technology. The company’s progress in preclinical trials and upcoming human trials underscores its commitment to transforming the CGM landscape.